These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 2454691)
21. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. Loeffler M; Diehl V; Pfreundschuh M; Rühl U; Hasenclever D; Nisters-Backes H; Sieber M; Tesch H; Franklin J; Geilen W; Bartels H; Cartoni C; Dölken G; Enzian J; Fuchs R; Gassmann W; Gerhartz H; Hagen-Aukamp U; Hiller E; Hinkelbein H; Hinterberger W; Kirchner H; Koch P; Krüger B; Schwarze EW J Clin Oncol; 1997 Jun; 15(6):2275-87. PubMed ID: 9196141 [TBL] [Abstract][Full Text] [Related]
22. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848 [TBL] [Abstract][Full Text] [Related]
23. [Recurrence of Hodgkin's disease after advanced primary stages. German Hodgkin's Study Group]. Fuchs R; Löffler M; Pfreundschuh M; Dölken G; Gerhartz H; Hagen-Aukamp U; Hiller E; Petsch S; Pflüger KH; Rühl U Med Klin (Munich); 1992 Nov; 87(11):555-62. PubMed ID: 1281905 [TBL] [Abstract][Full Text] [Related]
24. ABVD or BEACOPP Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ; Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705 [TBL] [Abstract][Full Text] [Related]
25. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens. Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149 [TBL] [Abstract][Full Text] [Related]
26. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ballova V; Rüffer JU; Haverkamp H; Pfistner B; Müller-Hermelink HK; Dühmke E; Worst P; Wilhelmy M; Naumann R; Hentrich M; Eich HT; Josting A; Löffler M; Diehl V; Engert A Ann Oncol; 2005 Jan; 16(1):124-31. PubMed ID: 15598949 [TBL] [Abstract][Full Text] [Related]
27. BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group. Rüffer JU; Ballova V; Glossmann J; Sieber M; Franklin J; Nogova L; Diehl V; Josting A; Leuk Lymphoma; 2005 Nov; 46(11):1561-7. PubMed ID: 16236610 [TBL] [Abstract][Full Text] [Related]
28. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. Hutchinson RJ; Fryer CJ; Davis PC; Nachman J; Krailo MD; O'Brien RT; Collins RD; Whalen T; Reardon D; Trigg ME; Gilchrist GS J Clin Oncol; 1998 Mar; 16(3):897-906. PubMed ID: 9508171 [TBL] [Abstract][Full Text] [Related]
29. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. Colonna P; Jais JP; Desablens B; Harousseau JL; Brière J; Boasson M; Lemevel A; Casassus P; Le Prisé PY; Guilhot F; Ghandour C; Lejeune F; Andrieu JM J Clin Oncol; 1996 Jun; 14(6):1928-35. PubMed ID: 8656262 [TBL] [Abstract][Full Text] [Related]
30. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. Brosteanu O; Hasenclever D; Loeffler M; Diehl V; Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867 [TBL] [Abstract][Full Text] [Related]
31. Prognosis of high dose chemotherapy/autologous bone marrow transplantation candidates not receiving this treatment after failure of primary therapy of Hodgkin's disease. Fuchs R; Löffler M; Pfreundschuh M; Dölken G; Gerhartz H; Hagen-Aukamp U; Hiller E; Petsch S; Pflüger KH; Rühl U Leuk Lymphoma; 1994 Jun; 14(1-2):79-89. PubMed ID: 7522721 [TBL] [Abstract][Full Text] [Related]
33. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP; Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253 [TBL] [Abstract][Full Text] [Related]
34. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014 [TBL] [Abstract][Full Text] [Related]
35. Advanced stage and unfavorable Hodgkin's disease in the Chinese-a 20-year experience. Chim CS; Kwong YL; Lie AK; Lee CK; Ho FC; Liang R Am J Hematol; 1999 Jul; 61(3):159-63. PubMed ID: 10398307 [TBL] [Abstract][Full Text] [Related]
36. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group. Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455 [TBL] [Abstract][Full Text] [Related]
37. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy. Muwakkit S; Geara F; Nabbout B; Farah RA; Shabb NS; Hajjar T; Khogali M Radiat Oncol Investig; 1999; 7(6):365-73. PubMed ID: 10644060 [TBL] [Abstract][Full Text] [Related]
38. Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90. Dieckmann K; Pötter R; Hofmann J; Heinzl H; Wagner W; Schellong G; Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):644-52. PubMed ID: 12788169 [TBL] [Abstract][Full Text] [Related]
39. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583 [TBL] [Abstract][Full Text] [Related]
40. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. Skoetz N; Trelle S; Rancea M; Haverkamp H; Diehl V; Engert A; Borchmann P Lancet Oncol; 2013 Sep; 14(10):943-52. PubMed ID: 23948348 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]